Healthcare-Associated Infections

^[1]

The one-minute consultant answer

A healthcare-associated infection (HAI) is an infection that was not present or incubating at the time of admission — operationally, one that develops 48 hours or more after admission, or within 30 days of a procedure (90 days if an implant was placed), or within 48 hours of discharge. The five device-associated HAIs that dominate clinical practice and exam questioning are catheter-related bloodstream infection (CRBSI, also called CLABSI), ventilator-associated pneumonia (VAP), catheter-associated urinary tract infection (CAUTI), surgical site infection (SSI), and Clostridioides difficile infection (CDI). Each has a defined clinical syndrome, a defined diagnostic strategy, a defined management pathway, and — critically — a defined evidence-based prevention bundle. The prevention of HAI is a systems activity: hand hygiene, care bundles, antimicrobial stewardship and device minimisation are the four pillars, and the physician's role is to implement them reliably and to remove devices promptly ^{[1] [2]}.

The core principle is that devices cause infections, and the safest device is the one that is not there. Every central venous catheter, urinary catheter, and endotracheal tube carries a daily risk of infection, and the single most effective prevention measure for all three is daily review of necessity with prompt removal. When the device cannot be removed, evidence-based care bundles reduce the infection risk substantially — the central line bundle reduced CLABSI rates by up to 66 per cent in the landmark Pronovost Michigan ICU study ^[1], and the ventilator bundle reduces VAP by approximately 40 per cent in meta-analytic data ^[4]. These bundles are not a menu of suggestions — they are a set of measures that, when delivered together and reliably, transform the safety of invasive devices.

For the physician managing a suspected HAI at the bedside, the approach is: first, identify the likely source (line, lungs, urine, wound, or colon); second, obtain appropriate cultures BEFORE starting or changing antibiotics; third, start empiric therapy calibrated to the likely organism and the local antibiogram; and fourth, de-escalate at 48 hours based on culture results. This connects directly to antimicrobial stewardship (see the dedicated topic): every HAI prevented is one fewer antibiotic course, one fewer selection pressure for resistance, and one fewer risk of CDI ^[8]. The exam will test you on the specific diagnostic criteria (especially paired blood cultures and differential time to positivity for CRBSI), the bundle components (especially the central line and ventilator bundles), the severity-stratified CDI therapy (especially the fidaxomicin-versus-vancomycin decision), and the distinction between asymptomatic bacteriuria and CAUTI (treating the former is a classic MCQ error).

---

References14ShowHide

1. [1]Pronovost P, Needham D, Berenholtz S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU N Engl J Med, 2006.PMID 17192537
2. [2]O'Grady NP, Alexander M, Burns LA, et al. Guidelines for the prevention of intravascular catheter-related infections Clin Infect Dis, 2011.PMID 21460264
3. [3]Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America Clin Infect Dis, 2009.PMID 19489710
4. [4]Martinez-Reviejo R, Tejada S, Jansson M, et al. Prevention of ventilator-associated pneumonia through care bundles: A systematic review and meta-analysis J Intensive Med, 2023.PMID 38028633
5. [5]Muscedere J, Rewa O, McKechnie K, et al. Subglottic secretion drainage for the prevention of ventilator-associated pneumonia: a systematic review and meta-analysis Crit Care Med, 2011.PMID 21478738
6. [6]Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America Clin Infect Dis, 2010.PMID 20175247
7. [7]Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery Am J Health Syst Pharm, 2013.PMID 23327981
8. [8]McDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) Clin Infect Dis, 2018.PMID 29462280
9. [9]Johnson S, Lavergne V, Skinner AM, et al. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults Clin Infect Dis, 2021.PMID 34164674
10. [10]Wilcox MH, Gerding DN, Poxton IR, et al. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection N Engl J Med, 2017.PMID 28121498
11. [11]Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection N Engl J Med, 2011.PMID 21288078
12. [12]van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile N Engl J Med, 2013.PMID 23323867
13. [13]Nicolle LE, Gupta K, Bradley SF, et al. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America Clin Infect Dis, 2019.PMID 30895288
14. [14]Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality N Engl J Med, 2005.PMID 16322602